Samsung Bioepis announced this week that it has gained regulatory approval in the Republic of Korea for its trastuzumab biosimilar, SB3.
Samsung Bioepis announced this week that it has gained regulatory approval in the Republic of Korea for its trastuzumab biosimilar, SB3.
The Korea Herald reports that the biosimilar, referenced on Herceptin, was granted a marketing approval by the Korean Ministry of Food and Drug Safety for the treatment of metastatic breast cancer, early breast cancer, and metastatic gastric cancer. Samsung Bioepis plans to sell the drug under the brand name Samfenet. The next steps for the biosimilar developer are selecting a marketing partner for commercializing the drug and completing drug pricing procedures for the Korean marketplace.
The Republic of Korea has thus far approved 3 other biosimilars made by Incheon-based Samsung Bioepis: etanercept (referenced on Enbrel), infliximab (referenced on Remicade), and adalimumab (referenced on Humira). Samsung Bioepis has already launched its etanercept and infliximab products, but awaits Korean patent expiry of Humira—in January 2019—before it will begin to sell its adalimumab treatment.
SB3 also earned a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) in September 2017. If SB3 is granted a final marketing authorization by the European Commission, the company plans to sell the biosimilar in the European marketplace under the brand name Ontruzant. The drug will be marketed in Europe by MSD (known as Merck in the United States), and is poised to become the first biosimilar trastuzumab available in the European marketplace.
Meanwhile, the United States awaits a trastuzumab biosimilar of its own; while Samsung Bioepis has not announced a filing for SB3 with the FDA, the US regulatory body is currently reviewing a trastuzumab biosimilar, MYL-1401O, developed by Mylan and Biocon. Though the drug had a Biosimilar User Fee Act (BsUFA) target date of September 3, 2017, Biocon announced in late August that the FDA would not issue a regulatory decision on the product until December 3.
What Stands in the Way of Biosimilar Use Across MENA Countries?
May 21st 2025Despite the clear promise of cost savings and expanded access, the path to integrating generics and biosimilars across the Middle East and North Africa (MENA) region is tangled in a web of distrust, inconsistent policies, and deep-rooted cultural preferences for branded drugs.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
The Trump Administration’s Drug Price Actions and Why US Prices Are Already Sky-High
May 17th 2025While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more complex web of development costs, profit incentives, and absent price controls—raising the question of whether any single policy, including potential drug tariffs, can truly untangle it.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Samsung Bioepis Report Signals Turning Point for US Biosimilars
May 1st 2025A wave of biosimilar approvals, aggressive pricing strategies, and a regulatory sea change are setting the stage for unprecedented momentum in the US biologics market, with 2025 already proving to be a landmark year in reshaping cost, access, and innovation across therapeutic areas.